Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Issue Date
2019-11-26
Metadata
Show full item recordAbstract
In this review, a general introduction to fragment-based drug design and the underlying concepts is given. General considerations and methodologies ranging from library selection/construction over biophysical screening and evaluation methods to in-depth hit qualification and subsequent optimization strategies are discussed. These principles can be generally applied to most classes of drug targets. The examples given for fragment growing, merging, and linking strategies at the end of the review are set in the fields of enzyme-inhibitor design and macromolecule-macromolecule interaction inhibition. Building upon the foundation of fragment-based drug discovery (FBDD) and its methodologies, we also highlight a few new trends in FBDD.Citation
Molecules. 2019;24(23):4309. Published 2019 Nov 26. doi:10.3390/molecules24234309.Affiliation
HIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.Publisher
MDPIJournal
Molecules (Basel, Switzerland)PubMed ID
31779114Type
ReviewOther
Language
enEISSN
1420-3049ae974a485f413a2113503eed53cd6c53
10.3390/molecules24234309
Scopus Count
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
Related articles
- [Fragment-based drug discovery: concept and aim].
- Authors: Tanaka D
- Issue date: 2010 Mar
- Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities.
- Authors: Huang B, Kang D, Zhan P, Liu X
- Issue date: 2015 Dec
- [In-silico approaches for fragment-based drug design].
- Authors: Takahashi O, Masuda Y, Muroya A, Furuya T
- Issue date: 2010 Mar
- Hit triage using efficiency indices after screening of compound libraries in drug discovery.
- Authors: Reitz AB, Smith GR, Tounge BA, Reynolds CH
- Issue date: 2009
- Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design.
- Authors: Sabat M, Dougan DR, Knight B, Lawson JD, Scorah N, Smith CR, Taylor ER, Vu P, Wyrick C, Wang H, Balakrishna D, Hixon M, Madakamutil L, McConn D
- Issue date: 2021 Sep 9